Is the combined use of insulin resistance indices, including adipokines, more reliable in metabolic syndrome?

Birgül KURAL, (Karadeniz Teknik Üniversitesi, Tıp Fakültesi, Biyokimya Anabilim Dalı, Trabzon, Türkiye)
Orhan DEĞER, (Karadeniz Teknik Üniversitesi, Tıp Fakültesi, Biyokimya Anabilim Dalı, Trabzon, Türkiye)
Cihangir EREM, (Karadeniz Teknik Üniversitesi, Tıp Fakültesi, İç Hastalıkları Anabilim Dalı, Endokrinoloji ve Metabolizma Hastalıkları Bilim Dalı, Trabzon, Türkiye)
Fulya YÜCESAN BALABAN, (Karadeniz Teknik Üniversitesi, Tıp Fakültesi, Biyokimya Anabilim Dalı, Trabzon, Türkiye)
Rezzan ALİYAZICIOĞLU, (Karadeniz Teknik Üniversitesi, Eczacılık Fakültesi, Trabzon, Türkiye)
Yaşam BARLAK (Gümüşhane Üniversitesi, Sağlık Bilimleri Yüksekokulu, Gümüşhane, Türkiye)
Turkish Journal of Medical Sciences
5 2
Yıl: 2014 Cilt: 44 Sayı: 6 Sayfa Aralığı: 1021 - 1028 Metin Dili: İngilizce İndeks Tarihi: 29-07-2022

Is the combined use of insulin resistance indices, including adipokines, more reliable in metabolic syndrome?

Öz:
Background/aim: To determine the levels of adipokines (leptin, adiponectin, resistin, and visfatin) and the indices of insulin sensitivity/ resistance, and to examine the relationship among them in patients with metabolic syndrome (MetS). Materials and methods: The study groups included 45 subjects with MetS (31 women/14 men), and 45 sex- and age-matched non-MetS healthy volunteers (31 women/14 men). The levels of adipokines were determined by enzyme-linked immunosorbent assay. Results: The levels of leptin and visfatin were significantly higher in the MetS than in the non-MetS subjects (P < 0.01). There was no difference in adiponectin levels in subjects with and without MetS (P = 0.052). Similarly, resistin did not show any statistically significant difference. A statistically significant positive correlation of leptin with insulin levels was observed, while negative correlations of visfatin levels with age, and resistin levels with the ratio of adiponectin to leptin, were found in the MetS (P < 0.05). The combination of adipokines, insulin resistance-sensitivity parameters, and MetS criteria parameters gave more significant differences than a single parameter. Conclusion: Since the parameters mentioned above might affect, interact with, and/or interfere with each other, the combinations of these parameters might give more reliable results to evaluate the insulin resistance/sensitivity in MetS patients.
Anahtar Kelime:

Konular: Cerrahi
Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
  • 1. Garg MK, Dutta MK, Mahalle N. Adipokines (adiponectin and plasminogen activator inhibitor-1) in metabolic syndrome. Indian J Endocrinol Metab 2012; 16: 116–123.
  • 2. Kotani K, Sakane N. Leptin:adiponectin ratio and metabolic syndrome in the general Japanese population. Korean J Lab Med 2011; 31: 162–166.
  • 3. Silva FM, de Almeida JC, Feoli AM. Effect of diet on adiponectin levels in blood. Nutr Rev 2011; 69: 599–612.
  • 4. Stofkova A. Resistin and visfatin: regulators of insulin sensitivity, inflammation, and immunity. Endocr Regul 2010; 44: 25–36.
  • 5. Yadav A, Jyoti P, Jain SK, Bhattacharjee J. Correlation of adiponectin and leptin with insulin resistance: a pilot study in healthy north Indian population. Ind J Clin Biochem 2011; 26: 193–196.
  • 6. La Cava A, Alviggi C, Matarese G. Unraveling the multiple roles of leptin in inflammation and autoimmunity. J Mol Med 2004; 82: 4–11.
  • 7. Jamaluddin MS, Weakley SM, Yao Q, Chen C. Resistin: functional roles and therapeutic considerations for cardiovascular disease. Br J Pharmacol 2012; 165: 622–632.
  • 8. Kamińska A, Kopczyńska E, Bronisz A, Zmudzińska M, Bieliński M, Borkowska A, Tyrakowski T, Junik R. An evaluation of visfatin levels in obese subjects. Endokrynol Pol 2010; 61: 169–173.
  • 9. Wang P, Vanhoutte PM, Miao CY. Visfatin and cardio-cerebrovascular disease. J Cardiovasc Pharmacol 2012; 59: 1–9.
  • 10. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486–2497.
  • 11. Vanizor Kural B, Değer O, Erem C, Balaban Yücesan F, Barlak Y, Turan İ, Aliyazıcıoğlu R. Sequence variant in the LPIN1 gene in patients with metabolic syndrome. Turk J Biochem 2013; 38: 280–285.
  • 12. Erem C, Arslan C, Hacihasanoglu A, Deger O, Topbas M, Ukinc K, Ersöz HO, Telatar M. Prevalence of obesity and associated risk factors in a Turkish population (Trabzon city, Turkey). Obes Res 2004; 12: 1117–1127.
  • 13. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412–419.
  • 14. Matsuhisa M, Yamasaki Y, Emoto M, Shimabukuro M, Ueda S, Funahashi T, Matsuzawa Y. A novel index of insulin resistance determined from the homeostasis model assessment index and adiponectin levels in Japanese subjects. Diabetes Res Clin Pract 2007; 77: 151–154.
  • 15. Lau CH, Muniandy S. Novel adiponectin-resistin (AR) and insulin resistance (IRAR) indexes are useful integrated diagnostic biomarkers for insulin resistance, type 2 diabetes and metabolic syndrome: a case control study. Cardiovasc Diabetol 2011; 10: 8.
  • 16. Lamia B, Chemla D, Richard C, Teboul JL. Clinical review: interpretation of arterial pressure wave in shock states. Crit Care 2005; 9: 601–606.
  • 17. Mirza S, Qu HQ, Li Q, Martinez PJ, Rentfro AR, McCormick JB, Fisher-Hoch SP. Adiponectin/leptin ratio and metabolic syndrome in a Mexican American population. Clin Invest Med 2011; 34: E290.
  • 18. Gupta V, Singh AK, Gupta V, Kumar S, Srivastava N, Jafar T, Pant AB. Association of circulating resistin with metabolic risk factors in Indian females having metabolic syndrome. Toxicol Int 2011; 18: 168–172.
  • 19. Kolsgaard ML, Wangensteen T, Brunborg C, Joner G, Holven KB, Halvorsen B, Aukrust P, Tonstad S. Elevated visfatin levels in overweight and obese children and adolescents with metabolic syndrome. Scand J Clin Lab Invest 2009; 69: 858– 864.
  • 20. Krzysik-Walker SM, Ocón-Grove OM, Maddineni SR, Hendricks GL, Ramachandran R. Is visfatin an adipokine or myokine? Evidence for greater visfatin expression in skeletal muscle than visceral fat in chickens. Endocrinology 2008; 149: 1543–1550.
  • 21. Kadowaki T, Yamauchi T, Kubota N, Hara K, Ueki K, Tobe K. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin Invest 2006; 116: 1784–1792.
  • 22. Jazet IM, Fogteloo AJ, Meinders AE. The relation between leptin and insulin remains when insulin secretion is disturbed. Eur J Intern Med 2006; 17: 109–114.
  • 23. De Luis DA, Gonzalez Sagrado M, Conde R, Aller R, Izaola O, Romero E. Effect of a hypocaloric diet on serum visfatin in obese non-diabetic patients. Nutrition 2008; 24: 517–521.
  • 24. Ferreira AF, Rezende JC, Vaikousi E, Akolekar R, Nicolaides KH. Maternal serum visfatin at 11-13 weeks of gestation in gestational diabetes mellitus. Clin Chem 2011; 57: 609–613.
  • 25. Wolfson N, Gavish D, Matas Z, Boaz M, Shargorodsky M. Relation of adiponectin to glucose tolerance status, adiposity, and cardiovascular risk factor load. Exp Diabetes Res 2012: 250621.
  • 26. Olszanecka-Glinianowicz M, Kocełak P, Janowska J, Skorupa A, Nylec M, Zahorska-Markiewicz B. Plasma visfatin and tumor necrosis factor-alpha (TNF-α) levels in metabolic syndrome. Kardiol Pol 2011; 69: 802–807.
  • 27. Jung CH, Rhee EJ, Choi JH, Bae JC, Yoo SH, Kim WJ, Park CY, Mok JO, Kim CH, Lee WY et al. The relationship of adiponectin/leptin ratio with homeostasis model assessment insulin resistance index and metabolic syndrome in apparently healthy Korean male adults. Korean Diabetes J 2010; 34: 237– 243.
  • 28. Inoue M, Maehata E, Yano M, Taniyama M, Suzuki S. Correlation between the adiponectin-leptin ratio and parameters of insulin resistance in patients with type 2 diabetes. Metabolism 2005; 54: 281–286.
  • 29. Norata GD, Raselli S, Grigore L, Garlaschelli K, Dozio E, Magni P, Catapano AL. Leptin:adiponectin ratio is an independent predictor of intima media thickness of the common carotid artery. Stroke 2007; 38: 2844–2846.
  • 30. Satoh N, Naruse M, Usui T, Tagami T, Suganami T, Yamada K, Kuzuya H, Shimatsu A, Ogawa Y. Leptin-to-adiponectin ratio as a potential atherogenic index in obese type 2 diabetic patients. Diabetes Care 2004; 27: 2488–2490.
  • 31. Stenvinkel P. Leptin and blood pressure—is there a link? Nephrol Dial Transplant 2000; 15: 1115–1117.
  • 32. Lambert M, O’Loughlin J, Delvin EE, Levy E, Chiolero A, Paradis G. Association between insulin, leptin, adiponectin and blood pressure in youth. J Hypertens 2009; 27: 1025–1032.
  • 33. Shatat IF, Freeman KD, Vuguin PM, Dimartino-Nardi JR, Flynn JT. Relationship between adiponectin and ambulatory blood pressure in obese adolescents. Pediatr Res 2009; 65: 691– 695.
  • 34. Furuhashi M, Ura N, Higashiura K, Murakami H, Tanaka M, Moniwa N, Yoshida D, Shimamoto K. Blockade of the reninangiotensin system increases adiponectin concentrations in patients with essential hypertension. Hypertension 2003; 42: 76–81.
  • 35. Islam N, Hossain M, Hafizur RM, Khan I, Rashid MA, Shefin SM, Haque ME, Faruque MO, Ali L. Fasting glucose to adiponectin ratio is associated with the development of type 2 diabetes mellitus . J Diabetol 2011; 3: 3.
  • 36. Makni E, Moalla W, Lac G, Aouichaoui C, Cannon D, Elloumi M, Tabka Z. The homeostasis model assessment-adiponectin (HOMA-AD) is the most sensitive predictor of insulin resistance in obese children. Ann Endocrinol (Paris) 2012; 73: 26–33.
  • 37. Moon JY, Park S, Ahn CM, Cho JR, Park CM, Ko YG, Choi D, Jeong MH, Jang Y, Chung N. Increase of metabolic syndrome score is an independent determinant of increasing pulse pressure. Yonsei Med J 2008; 49: 63–70.
  • 38. Emre A, Oz D, Yesilcimen K, Sayar N, Ergun D. Impact of the metabolic syndrome on aortic pulse pressure and ascending aortic pulsatility in patients with angiographically normal coronary arteries. Can J Cardiol 2009; 25: 411–414.
  • 39. Baban RS, Kasar KA, Al-Karawi IN. Fasting glucose to leptin ratio as a new diagnostic marker in patients with diabetes mellitus. Oman Med J 2010; 25: 269–275.
  • 40. Quon MJ. Limitations of the fasting glucose to insulin ratio as an index of insulin sensitivity. J Clin Endocrinol Metab 2001; 86: 4615–4617.
  • 41. Marotta T, Russo BF, Ferrara LA. Triglyceride-to-HDLcholesterol ratio and metabolic syndrome as contributors to cardiovascular risk in overweight patients. Obesity (Silver Spring) 2010; 18: 1608–1613.
  • 42. Kawamoto R, Tabara Y, Kohara K, Miki T, Kusunoki T, Takayama S, Abe M, Katoh T, Ohtsuka N. Relationships between lipid profiles and metabolic syndrome, insulin resistance and serum high molecular adiponectin in Japanese community-dwelling adults. Lipids Health Dis 2011; 10: 79.
  • 43. Lamharzi N, Renard CB, Kramer F, Pennathur S, Heinecke JW, Chait A, Bornfeldt KE. Hyperlipidemia in concert with hyperglycemia stimulates the proliferation of macrophages in atherosclerotic lesions: potential role of glucose-oxidized LDL. Diabetes 2004; 53: 217–225.
  • 44. Okon EB, Chung AW, Zhang H, Laher I, van Breemen C. Hyperglycemia and hyperlipidemia are associated with endothelial dysfunction during the development of type 2 diabetes. Can J Physiol Pharmacol 2007; 85: 562–567.
  • 45. Lai SW, Tan CK, Ng KC. Epidemiology of hyperglycemia in elderly persons. J Gerontol A Biol Sci Med Sci 2000; 55: M257– M259.
  • 46. Finn PF, Dice JF. Proteolytic and lipolytic responses to starvation. Nutrition 2006; 22: 830–844.
APA KURAL B, DEĞER O, EREM C, YÜCESAN BALABAN F, ALİYAZICIOĞLU R, BARLAK Y (2014). Is the combined use of insulin resistance indices, including adipokines, more reliable in metabolic syndrome?. , 1021 - 1028.
Chicago KURAL BİRGÜL,DEĞER Orhan,EREM Cihangir,YÜCESAN BALABAN Fulya,ALİYAZICIOĞLU Rezzan,BARLAK YASAM Is the combined use of insulin resistance indices, including adipokines, more reliable in metabolic syndrome?. (2014): 1021 - 1028.
MLA KURAL BİRGÜL,DEĞER Orhan,EREM Cihangir,YÜCESAN BALABAN Fulya,ALİYAZICIOĞLU Rezzan,BARLAK YASAM Is the combined use of insulin resistance indices, including adipokines, more reliable in metabolic syndrome?. , 2014, ss.1021 - 1028.
AMA KURAL B,DEĞER O,EREM C,YÜCESAN BALABAN F,ALİYAZICIOĞLU R,BARLAK Y Is the combined use of insulin resistance indices, including adipokines, more reliable in metabolic syndrome?. . 2014; 1021 - 1028.
Vancouver KURAL B,DEĞER O,EREM C,YÜCESAN BALABAN F,ALİYAZICIOĞLU R,BARLAK Y Is the combined use of insulin resistance indices, including adipokines, more reliable in metabolic syndrome?. . 2014; 1021 - 1028.
IEEE KURAL B,DEĞER O,EREM C,YÜCESAN BALABAN F,ALİYAZICIOĞLU R,BARLAK Y "Is the combined use of insulin resistance indices, including adipokines, more reliable in metabolic syndrome?." , ss.1021 - 1028, 2014.
ISNAD KURAL, BİRGÜL vd. "Is the combined use of insulin resistance indices, including adipokines, more reliable in metabolic syndrome?". (2014), 1021-1028.
APA KURAL B, DEĞER O, EREM C, YÜCESAN BALABAN F, ALİYAZICIOĞLU R, BARLAK Y (2014). Is the combined use of insulin resistance indices, including adipokines, more reliable in metabolic syndrome?. Turkish Journal of Medical Sciences, 44(6), 1021 - 1028.
Chicago KURAL BİRGÜL,DEĞER Orhan,EREM Cihangir,YÜCESAN BALABAN Fulya,ALİYAZICIOĞLU Rezzan,BARLAK YASAM Is the combined use of insulin resistance indices, including adipokines, more reliable in metabolic syndrome?. Turkish Journal of Medical Sciences 44, no.6 (2014): 1021 - 1028.
MLA KURAL BİRGÜL,DEĞER Orhan,EREM Cihangir,YÜCESAN BALABAN Fulya,ALİYAZICIOĞLU Rezzan,BARLAK YASAM Is the combined use of insulin resistance indices, including adipokines, more reliable in metabolic syndrome?. Turkish Journal of Medical Sciences, vol.44, no.6, 2014, ss.1021 - 1028.
AMA KURAL B,DEĞER O,EREM C,YÜCESAN BALABAN F,ALİYAZICIOĞLU R,BARLAK Y Is the combined use of insulin resistance indices, including adipokines, more reliable in metabolic syndrome?. Turkish Journal of Medical Sciences. 2014; 44(6): 1021 - 1028.
Vancouver KURAL B,DEĞER O,EREM C,YÜCESAN BALABAN F,ALİYAZICIOĞLU R,BARLAK Y Is the combined use of insulin resistance indices, including adipokines, more reliable in metabolic syndrome?. Turkish Journal of Medical Sciences. 2014; 44(6): 1021 - 1028.
IEEE KURAL B,DEĞER O,EREM C,YÜCESAN BALABAN F,ALİYAZICIOĞLU R,BARLAK Y "Is the combined use of insulin resistance indices, including adipokines, more reliable in metabolic syndrome?." Turkish Journal of Medical Sciences, 44, ss.1021 - 1028, 2014.
ISNAD KURAL, BİRGÜL vd. "Is the combined use of insulin resistance indices, including adipokines, more reliable in metabolic syndrome?". Turkish Journal of Medical Sciences 44/6 (2014), 1021-1028.
Sayfa Oluşturulma Tarihi
23-04-2024 0:34

İLETİŞİM

TÜBİTAK ULAKBİM TR Dizin

Yüzüncüyıl, İşçi Blokları Mahallesi

Muhsin Yazıcıoğlu Caddesi No:51/C

06530 Çankaya / ANKARA +90 (312) 298 92 00

trdizin@tubitak.gov.tr

TÜBİTAK ULAKBİM Ulusal Akademik Ağ ve Bilgi Merkezi Cahit Arf Bilgi Merkezi © Tüm Hakları Saklıdır. Gizlilik Politikası Kullanım Şartları